苯醌

苯醌用途

【用途一】
用于制对苯二酚，用作染料和医药中间体、橡胶防老剂、阻聚剂、抗氧化剂、显影剂等
【用途二】
用作氧化剂，也用于有机合成
【用途三】
染料和医药的中间体。制造对苯二酚和橡胶防老剂，丙烯腈和醋酸乙烯聚合引发剂以及氧化剂等。
【用途四】
106-51-4（苯醌）用于石油化工产品阻聚以及染料、医药中间体的制造等领域。
【用途五】
用作毒芹碱、吡啶、氮杂茂、酪氨酸和对苯二酚的定性检定。分析中用于氨基酸的测定。染料和医药的中间体。制造对苯二酚和橡胶防老剂，丙烯腈和醋酸乙烯聚合引发剂以及氧化剂等。

苯醌名称

[ CAS 号 ]:
106-51-4

[ 中文名 ]:
苯醌

[ 英文名 ]:
1,4-Benzoquinone

[中文别名 ]:

[英文别名 ]:

2,5-Cyclohexadiene-1,4-dione
p-Benzoquinone,Quinone
para-benzoquinone
Thiophene,5-dibromo
p-quinone
2,5-dibromothiophen
para-quinone
benzoquinone
2,5-dibromo thiophene
MFCD00001591

苯醌物理化学性质

[ 密度 ]:
1.3±0.1 g/cm3

[ 沸点 ]:
174.0±15.0 °C at 760 mmHg

[ 熔点 ]:
113-115 °C(lit.)

[ 分子式 ]:
C₆H₄O₂

[ 分子量 ]:
108.095

[ 闪点 ]:
59.3±17.4 °C

[ 精确质量 ]:
108.021126

[ PSA ]:
34.14000

[ LogP ]:
0.26

[ 外观性状 ]:
黄色至绿色结晶固体

[ 蒸汽密度 ]:
3.73 (vs air)

[ 蒸汽压 ]:
1.2±0.3 mmHg at 25°C

[ 折射率 ]:
1.543

[ 储存条件 ]:
库房通风低温干燥,与氧化剂、食品添加剂分开存放

[ 稳定性 ]:
Stable, but light sensitive. Incompatible with strong oxidizing agents. Flammable.

[ 水溶解性 ]:
10 g/L (25 ºC)

苯醌MSDS

详细MSDS(安全技术说明书)

苯醌毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DK2625000

CHEMICAL NAME :: p-Benzoquinone

CAS REGISTRY NUMBER :: 106-51-4

LAST UPDATED :: 199712

DATA ITEMS CITED :: 60

MOLECULAR FORMULA :: C6-H4-O2

MOLECULAR WEIGHT :: 108.10

WISWESSER LINE NOTATION :: L6V DVJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 130 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 30 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 5600 ug/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 100 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 8500 ug/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Behavioral - muscle contraction or spasticity Lungs, Thorax, or Respiration - cyanosis

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 93800 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: 296 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 800 mg/kg/29W-C

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Skin and Appendages - tumors

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 6326 mg/kg/43W-C

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Skin and Appendages - tumors

TYPE OF TEST :: Micronucleus test

MUTATION DATA

TYPE OF TEST :: Mutation test systems - not otherwise specified

TEST SYSTEM :: Rodent - rabbit Bone marrow

REFERENCE :: AJIMD8 American Journal of Industrial Medicine. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 7,485,1985 *** REVIEWS *** ACGIH TLV-TWA 0.44 mg/m3 (0.1 ppm) DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 15,255,1977 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 15,255,1977 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 *** U.S. STANDARDS AND REGULATIONS *** MSHA STANDARD-air:TWA 0.1 ppm (0.4 mg/m3) DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: 3,221,1971 OSHA PEL (Gen Indu):8H TWA 0.1 ppm (0.4 mg/m3) CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1910.1000,1994 OSHA PEL (Construc):8H TWA 0.1 ppm (0.4 mg/m3) CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1926.55,1994 OSHA PEL (Shipyard):8H TWA 0.1 ppm (0.4 mg/m3) CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1915.1000,1993 OSHA PEL (Fed Cont):8H TWA 0.1 ppm (0.4 mg/m3) CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 41,50-204.50,1994 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-ARAB Republic of Egypt:TWA 0.1 ppm (0.4 mg/m3) JAN 1993 OEL-AUSTRALIA:TWA 0.1 ppm (0.4 mg/m3) JAN 1993 OEL-AUSTRIA:TWA 0.1 ppm (0.4 mg/m3) JAN 1993 OEL-BELGIUM:TWA 0.1 ppm (0.44 mg/m3) JAN 1993 OEL-DENMARK:TWA 0.1 ppm (0.4 mg/m3) JAN 1993 OEL-FINLAND:TWA 0.1 ppm (0.4 mg/m3);STEL 0.3 ppm;Skin JAN 1993 OEL-FRANCE:TWA 0.1 ppm (0.4 mg/m3);STEL 0.3 ppm (1.5 mg/m3) JAN 1993 OEL-GERMANY:TWA 0.1 ppm (0.4 mg/m3) JAN 1993 OEL-THE NETHERLANDS:TWA 0.1 ppm (0.4 mg/m3) JAN 1993 OEL-THE PHILIPPINES:TWA 5 ppm (15 mg/m3) JAN 1993 OEL-RUSSIA:STEL 0.05 mg/m3 JAN 1993 OEL-SWEDEN:TWA 0.1 ppm (0.4 mg/m3);STEL 0.3 ppm (1.3 mg/m3) JAN 1993 OEL-SWITZERLAND:TWA 0.1 ppm (0.4 mg/m3);STEL 0.2 ppm (0.8 mg/m3) JAN 1993 OEL-TURKEY:TWA 0.1 ppm (0.4 mg/m3) JAN 1993 OEL-UNITED KINGDOM:TWA 0.1 ppm (0.4 mg/m3);STEL 0.3 ppm JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO QUINONE-air:10H TWA 0.1 ppm REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992 NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 66950 No. of Facilities: 145 (estimated) No. of Industries: 3 No. of Occupations: 6 No. of Employees: 3292 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 66950 No. of Facilities: 1228 (estimated) No. of Industries: 17 No. of Occupations: 18 No. of Employees: 15511 (estimated) No. of Female Employees: 1274 (estimated)

苯醌安全信息

[ 符号 ]:

GHS06, GHS09

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301 + H331-H315-H319-H335-H410

[ 警示性声明 ]:
P261-P273-P301 + P310 + P330-P304 + P340 + P312-P403 + P233-P501

[ 个人防护装备 ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T:Toxic

[ 风险声明 (欧洲) ]:
R23/25;R36/37/38;R50

[ 安全声明 (欧洲) ]:
S26-S28-S45-S61-S28A-S23-S16

[ 危险品运输编码 ]:
UN 2587 6.1/PG 2

[ WGK德国 ]:
3

[ RTECS号 ]:
DK2625000

[ 包装等级 ]:
II

[ 危险类别 ]:
6.1

[ 海关编码 ]:
2914700090

苯醌上下游产品

苯醌上游产品

苯醌下游产品

苯醌制备

1.将苯胺溶于稀硫酸中，经二氧化锰氧化，用蒸汽蒸馏法分离提纯，结晶、脱水、干燥，得成品。在工业生产中，这一过程也是生产对苯二酚的中间步骤，在某些场合，例如试剂生产药物制造，也采用以对苯二酚为原料，氧化制备对苯醌。原料消耗定额：苯胺2000kg/t、硫酸（93%）8500kg/t、软锰矿粉（含锰60-65%）9500kg/t。

2.将苯胺溶于稀硫酸中，经二氧化锰氧化，用蒸气直接蒸馏法进行分离提纯，再经结晶、脱水、干燥，即得产品。

3.电化学氧化合成　采用氯化三乙基苄基铵（BnEt3NCl）为相转移催化剂，以苯为原料，H2SO4、Na2SO4为支持电解质，在铅基二氧化铅阳极上电化学氧化合成对苯醌。优化的工艺条件是：BnEt3NCl含量0.1%，苯为16%或4%，Na2SO42%，温度40℃，电流密度2.5A/dm²，电流效率大于38%，最大产率达63%。

苯醌海关

[ 海关编码 ]: 2914690090

[ 中文概述 ]:
2914690090 其他醌. 增值税率:17.0% 退税率:9.0% 监管条件:无最惠国关税:5.5% 普通关税:30.0%

[ Summary ]:
2914690090 other quinones。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:5.5%。General tariff:30.0%

苯醌文献

Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders.

J. Neuropathol. Exp. Neurol. 74 , 1093-118, (2015)

Despite effective viral suppression through combined antiretroviral therapy (cART), approximately half of HIV-positive individuals have HIV-associated neurocognitive disorders (HAND). Studies of antir...

Green tea polyphenol (-)-epigallocatechin-3-gallate triggered hepatotoxicity in mice: responses of major antioxidant enzymes and the Nrf2 rescue pathway.

Toxicol. Appl. Pharmacol. 283(1) , 65-74, (2015)

(-)-Epigallocatechin-3-gallate (EGCG), a constituent of green tea, has been suggested to have numerous health-promoting effects. On the other hand, high-dose EGCG is able to evoke hepatotoxicity. In t...

Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.

Oncotarget 6 , 16488-506, (2015)

Malignant melanoma is the most dangerous type of skin cancer. Although recent progress in treatment has been achieved, lack of response, drug resistance and relapse remain major problems. The tumor su...

更多文献

苯醌